Clinical Trial Update: Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating irinotecan hydrochloride, temozolomide, and dinutuximab with or without eflornithine for relapsed or refractory neuroblastoma; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Camptosar (irinotecan)
• Eflornithine (eflornithine)
• Temodar (Temozolomide)
• UNITUXIN (dinutuximab)

Snippet

Sponsor: Children's Oncology Group | Conditions: High Risk Neuroblastoma, Recurrent Neuroblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-21